Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 5/20 | 0.49 |
| ▸ | NOS2 | P35228 | 5/20 | 0.49 |
| ▸ | NOS3 | P29474 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GGT1 | P19440 | 1/20 | 0.36 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cindunistat SCHEMBL5644203 | 1.00 | NOS1 (0.49) | NOS1NOS2NOS3TSHRGGT1 | |
| Cindunistat SCHEMBL14572932 | 1.00 | NOS1 (0.49) | NOS1NOS2NOS3TSHRGGT1 | |
| Cindunistat SCHEMBL27623381 | 0.98 | NOS1 (0.51) | NOS1NOS2NOS3TSHRGGT1 | |
| Cindunistat SCHEMBL1843640 | 0.98 | NOS1 (0.51) | NOS1NOS2NOS3TSHRGGT1 | |
| Cindunistat SCHEMBL5640418 | 0.98 | NOS1 (0.51) | NOS1NOS2NOS3TSHRGGT1 | |
| Cindunistat SCHEMBL1842090 | 0.93 | NOS1 (0.43) | NOS1NOS2NOS3TSHRGGT1 | |
| Cindunistat SCHEMBL6313297 | 0.93 | NOS1 (0.43) | NOS1NOS2NOS3TSHRGGT1 | |
| Cindunistat SCHEMBL1841632 | 0.92 | NOS1 (0.46) | NOS1NOS2NOS3TSHRGGT1 | |
| Cindunistat SCHEMBL29379550 | 0.92 | NOS1 (0.46) | NOS1NOS2NOS3TSHRGGT1 | |
| Cindunistat SCHEMBL27623377 | 0.92 | NOS1 (0.46) | NOS1NOS2NOS3TSHRGGT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 927 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025049740-A1 | COMPOSITIONS COMPRISING BIOMIMETIC PROTEOGLYCAN CONSTRUCTS | VILLANOVA UNIVERSITY (US) | 2025-03-06 | — | — | WO | claimed |
| WO-2024124357-A1 | DIAGNOSIS AND TREATMENT OF LONG-COVID | LONDON HEALTH SCIENCES CENTRE RESEARCH INC. (CA) | 2024-06-20 | — | — | WO | claimed |
| WO-2023076811-A1 | COMBINATION THERAPIES WITH CHIMERIC ANTIGEN RECEPTORS | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2023-05-04 | — | — | WO | claimed |
| US-20210060123-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2021-03-04 | — | — | US | claimed |
| US-20180161392-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2018-06-14 | — | — | US | claimed |
| EP-2825208-B1 | P75NTR NEUROTROPHIN BINDING PROTEIN FOR THERAPEUTIC USE | LEVICEPT LTD (GB) | 2017-05-17 | — | — | EP | claimed |
| US-20150037335-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2015-02-05 | — | — | US | claimed |
| EP-2175728-B1 | SODIUM CHANNEL INHIBITORS | ICAGEN INC (US) | 2014-09-10 | — | — | EP | claimed |
| EP-1603872-B1 | S-[2-[(1-IMINOETHYL)AMINO]ETHYL]-2-METHYL-L-CYSTEINE MALEATE HYDROCHLORIDE CRYSTALLINE SALT | PHARMACIA CORP (US) | 2011-05-18 | — | — | EP | claimed |
| US-20090111837-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN | PFIZER INC. | 2009-04-30 | — | — | US | claimed |
| WO-2004081073-A2 | METHODS FOR SELECTIVELY REMOVING COUNTERIONS FROM COMPOUNDS AND COMPOUNDS DERIVED FROM SUCH METHODS | PHARMACIA CORPORATION (US) | 2004-09-23 | — | — | WO | claimed |
| WO-2004060352-A1 | NON-HYGROSCOPIC FORMULATION COMPRISING A HYDROSCOPIC DRUG | PHARMACIA CORPORATION (US) | 2004-07-22 | — | — | WO | claimed |
| US-20040077639-A1 | Methods for the treatment of respiratory diseases and conditions using a selective iNOS inhibitor | MANNING PAMELA T (US) | 2004-04-22 | — | — | US | claimed |
| EP-1265859-A2 | AMIDINO COMPOUNDS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | Pharmacia Corporation (US) | 2002-12-18 | — | — | EP | claimed |
| EP-1265860-A1 | AMIDINO COMPOUND AND SALTS THEREOF USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | Pharmacia Corporation (US) | 2002-12-18 | — | — | EP | claimed |
| US-20020111493-A1 | Amidino compounds useful as nitric oxide synthase inhibitors | PHARMACIA LLC | 2002-08-15 | — | — | US | claimed |
| US-6403830-B2 | A S-(2-(1-IMINOETHYL)AMINO)ETHYL)-2-METHYL-L-CYSTEINE AND SALTS | PHARMACIA CORPORATION | 2002-06-11 | — | — | US | claimed |
| US-20020019563-A1 | Amidino compound and salts thereof useful as nitric oxide synthase inhibitors | PHARMACIA LLC | 2002-02-14 | — | — | US | claimed |
| WO-2001072703-A1 | AMIDINO COMPOUND AND SALTS THEREOF USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | PHARMACIA CORPORATION (US) | 2001-10-04 | — | — | WO | claimed |
| WO-2001072702-A2 | AMIDINO COMPOUNDS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | PHARMACIA CORPORATION (US) | 2001-10-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077639-A1 | Methods for the treatment of respiratory diseases and conditions using a selective iNOS inhibitor | NOS2, NOS1, NOS3 | NOS1 2/4885NOS2 1/4885NOS3 3/4885 |
| US-20020111493-A1 | Amidino compounds useful as nitric oxide synthase inhibitors | NOS2, NOS1, NOS3 | NOS1 2/4885NOS2 1/4885NOS3 3/4885 |
| US-20020019563-A1 | Amidino compound and salts thereof useful as nitric oxide synthase inhibitors | NOS2, NOS1, NOS3 | NOS1 2/4885NOS2 1/4885NOS3 3/4885 |
| US-20090111837-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN | PDE7A, PDE7B, PDE3A | NOS1 530/4885NOS2 508/4885NOS3 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.